The first assumption most clinics make about patient data in marketing is the wrong one: that it falls under the UAE's general data protection law, the same law that governs a retailer's mailing list. It doesn't. Health data that is already regulated by its own sector legislation is explicitly carved out of the general law's scope, which means the rules that actually apply are stricter and more specific than most marketing teams assume — and they reach further into the ordinary marketing stack than a CRM export or a retargeting pixel might suggest.
The law that actually governs this
Federal Decree-Law No. 45 of 2021 on the Protection of Personal Data is the UAE's general data protection law, and it exempts personal health data that is already subject to its own sector legislation from its scope. For a clinic, the operative instrument is Federal Law No. 2 of 2019 Concerning the Use of ICT in Health Fields, which sets confidentiality and security obligations for health data specifically and requires consent before that data is shared with or accessed by other parties. Where marketing data genuinely sits outside health data — a general enquiry's name, phone number and email, not tied to a diagnosis or treatment — the general law's direct-marketing rules still apply: consent must be freely given, specific, informed and unambiguous, with no pre-ticked boxes and a working opt-out that is as easy to use as opting in.
The fact that should change how you evaluate a marketing platform
Dubai Health Authority's current professional-conduct standard states plainly that health facilities must ensure health data is stored within the UAE and not transferred, processed, or stored outside the country unless specifically authorised by the relevant health authority in coordination with the government ministry. That single requirement is the most commercially significant thing in this article, because it directly implicates the marketing stack most clinics already run: a CRM, an email platform, or an ad-pixel vendor hosted on servers outside the UAE is operating outside this standard if it stores or processes patient-identifiable data without that authorisation. Before adopting or continuing to use any marketing tool that touches patient data, it is worth asking plainly where that vendor actually stores it.
Marketing counts as a separate use, needing separate consent
DHA's data protection and confidentiality policy treats marketing explicitly as a "secondary use" of patient data, distinct from the consent a patient gives for their treatment — research, public health reporting, clinical audit and marketing are all named as secondary uses that need their own, separate consent from the patient. A patient who consented to treatment did not, by that act, consent to being added to a marketing list, entered into a review-request workflow, or included in a remarketing audience. That consent has to be captured on its own terms.
Why you can't just upload a patient list as an ad audience
Both major ad platforms independently restrict what a clinic can do with patient-related data in advertising, and this is a technical constraint as much as a policy one. Meta classifies health and wellness properties and limits what conversion and audience data can flow back through its pixel and Conversions API for those properties. Google's personalised advertising policy goes further: for content addressing chronic conditions, intimate-body-part health issues, invasive procedures, disabilities, or mental-health counselling, advertiser-curated audiences — customer match, uploaded lists, CRM-based remarketing — are not permitted at all, and only Google's own predefined audience categories can be used. Uploading a patient list as a Custom Audience for this kind of content is not simply a policy risk; for a real slice of clinic marketing, it is technically restricted at the platform level.
What keeps the boundary clean in practice
A few habits, treated as operational hygiene rather than legal citation, do most of the work: segmenting the CRM so clinical fields like diagnosis, treatment and visit history are never exported into a general marketing or remarketing list; capturing marketing consent separately from clinical consent, at the point a lead is captured, rather than assuming one covers the other; and periodically auditing which third-party tools — CRM, email platform, review-request tool, ad pixels — actually receive patient-identifiable data, then minimising that list to what is genuinely needed.
That is HEYA's own recommendation for how to run this day to day, not a citation of a specific regulation — the law tells you what requires consent and where data must live; how you organise your marketing stack around that is a judgement call. It is also worth noting that a clinic operating inside a free zone with its own data regime, such as DIFC or ADGM, may sit under a different framework than mainland UAE rules, and this article does not assume one applies universally.
None of this is legal advice. Confirm current data protection and health-data obligations — and which regime applies to your specific facility — with a UAE data protection or legal advisor before finalising any data-handling policy, since these obligations are exactly the kind of thing that should be checked against the current text, not against a marketing article.
This sits alongside the wider question of how a practice positions itself by specialty rather than by discount — the data discipline described here is what makes a specialty's patient-acquisition marketing sustainable rather than a one-time list of names nobody can legally use again.
